Table 2.

First-line therapy and response in EBV⁺ DLBCL-NOS

	EBV+ DLBCL-NOS	≤50 y	>50 y	P
First-line therapy, n	69*	23	46*
Intent-to-cure therapy	56 (81)	23 (100)	33 (72)	.003
Immunochemotherapy ± RT	41 (73)	16 (70)	25 (76)	.760
Chemotherapy ± RT, n (%)	15 (27)	7 (30)	8 (24)
ASCT	3 (4)	3 (13)	0	.03
Palliative care	13 (19)	0	13 (28)
Response to first-line intent-to-cure therapy, n	56	23	33
CR	41 (73)	21 (91)	20 (61)	.014
PD	10 (18)	0	10 (30)	.003
NA (death other cause)	5 (9)	2 (9)	3 (9)	>.99
Follow-up and survival, n	70	23	47
Median follow-up, months	48	43.5	48
Median PFS, months	NR	NR	6.6
Median OS, months	NR	NR	10.9

Data are presented as n (%) of patients, unless otherwise indicated.

ASCT, autologous stem cell transplantation; HL, Hodgkin lymphoma; NA, not assessed; NR, not reached; PR, partial response; RT, radiation therapy.

^*Missing data (n = 1).